By Paul Armentano, NORML
The prolonged daily administration of cannabinoids is associated with a reduction in migraine headache frequency, according to clinical trial data presented at the 3rd Congress of the European Academy of Neurology.
Italian researchers compared the efficacy of oral cannabinoid treatments versus amitriptyline – an anti-depressant commonly prescribed for migraines – in 79 chronic migraine patients over a period of three months. Subjects treated daily with a 200mg dose of a combination of THC and CBD achieved a 40 percent reduction in migraine frequency – a result that was similar to the efficacy of amitriptyline therapy.
Subjects also reported that cannabinoid therapy significantly reduced acute migraine pain, but only when taken at doses above 100mg. Oral cannabinoid treatment was less effective among patients suffering from cluster headaches.